Alexandra K. Frye

Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease

Sebastiaan P. van Kessel, Alexandra K. Frye, Ahmed O. El‐Gendy et al. · Nature Communications · 2019 · 492 citations · Full text

Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells

Rebekka Duhen, Carmen Ballesteros‐Merino, Alexandra K. Frye et al. · Nature Communications · 2021 · 150 citations · Full text

Neoadjuvant Therapy, Immunology, Immunoediting +24

PD-1 and ICOS coexpression identifies tumor-reactive CD4+ T cells in human solid tumors

Rebekka Duhen, Olivier Fesneau, Kimberly Samson et al. · Journal of Clinical Investigation · 2022 · 68 citations · Full text

T-regulatory Cell, Immunology, Antigen Processing +16

Identification of the Abundant Hydroxyproline-Rich Glycoproteins in the Root Walls of Wild-Type Arabidopsis, an ext3 Mutant Line, and Its Phenotypic Revertant

Yuning Chen, Dening Ye, Michael Held et al. · Plants · 2015 · 23 citations · Full text

Botany, Genetics, Glycobiology +21

Gut bacterial tyrosine decarboxylases restrict the bioavailability of levodopa, the primary treatment in Parkinson’s disease

Sebastiaan P. van Kessel, Alexandra K. Frye, Ahmed O. El‐Gendy et al. · 2018 · 10 citations · Full text